OakChart

Medicinova Inc

MNOVHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:53 PM ET

1.40+0.00 (0.36%)
2026-11-11 21:53 CET
Market cap
68.91 USD m
Revenue, TTM
0.92 USD m
Net income, TTM
-10.75 USD m
Free cash flow, TTM
-9.12 USD m
EPS diluted, TTM
-0.22
P/E
-
Compare

Price

MNOV against its 20, 50 and 200-day averages
2050200beat
2.003.004.003.7M7.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MNOVclose 1.4120-day 1.4250-day 1.79200-day 1.501.4152w high52w low

64.0% under the 52-week high of 3.90 on 17 Sep 2026. 52-week low 1.22 on 15 Jun 2026. Last 15 sessions, 12.2% high to low

Volume 0.05× normal · the line is the 50-bar volume average

Profile

MNOV
52-week range, 7% of the way up
1.223.90

MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Employees6
IPODec 07, 2006
Beta0.71
ATR, 14d0.10
Rel volume0.05
Short float0.61%
Insider own5.12%
Inst own23.88%

Snapshot

6 groups

Valuation

Index-
Market Cap69.16M
Enterprise Value43.86M
Income-10.75M
Sales0.92M
Book/sh0.76
Cash/sh0.52
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees6
IPODec 07, 2006

Ratios

P/E-
Forward P/E-
PEG-
P/S75.17
P/B1.86
P/C2.72
P/FCF-
EV/EBITDA-
EV/Sales47.67
Quick Ratio8.75
Current Ratio8.75
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.22
EPS next Y-0.45
EPS next Q-0.06
EPS this Y-6.25%
EPS next Y-75.16%
EPS next 5Y-
EPS past 3/5Y5.19% 4.75%
Sales past 3/5Y- -
EPS Y/Y TTM9.14%
Sales Y/Y TTM583.87%
EPS Q/Q29.75%
Sales Q/Q240.60%
EarningsAug 13 AMC
EPS/Sales Surpr.28.91% 512.00%

Ownership

Insider Own5.12%
Insider Trans-20.25%
Inst Own23.88%
Inst Trans-0.59%
ROA-23.83%
ROE-25.56%
ROIC-28.85%
Gross Margin31.14%
Oper. Margin-1287.41%
Profit Margin-1168.20%
SMA20-1.11%
SMA50-21.32%
SMA200-6.51%
Trades-

Technical

Shs Outstand49.22M
Shs Float46.70M
Short Float0.61%
Short Ratio0.87
Short Interest0.29M
52W High3.90 -63.97%
52W Low1.22 15.16%
Volatility5.59% 5.16%
ATR (14)0.10
RSI (14)40.18
Beta0.71
Rel Volume0.05
Avg Volume327.50K
Volume17,529

Performance

Perf Week-3.10%
Perf Month-6.33%
Perf Quarter7.25%
Perf Half Y2.55%
Perf YTD7.25%
Perf Year-12.73%
Perf 3Y-21.07%
Perf 5Y-59.74%
Perf 10Y-80.70%
Recom1.00
Target Price8.25
Prev Close1.40
Price1.40
Change %0.36%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Sep 17, 2026InitiatedRRoth CapitalBuy$6+327.0%
Mar 16, 2026InitiatedHH.C. WainwrightBuy$10+611.7%
Mar 10, 2021InitiatedMMaxim GroupBuy$15+967.6%
Mar 25, 2019ResumedBB. Riley FBRBuy$22+1,465.8%
Mar 28, 2018InitiatedBB. Riley FBR, Inc.Buy$22+1,465.8%
Apr 18, 2017InitiatedCCredit SuisseOutperform
Jan 04, 2013ReiteratedLLadenburg ThalmannBuy$10.50 → $6+327.0%
May 24, 2012DowngradeMMLV & CoBuy → Hold
Oct 18, 2011ReiteratedMMLV CapitalBuy$13 → $6+327.0%
Jun 22, 2011InitiatedGGlobal Hunter SecuritiesBuy$4+184.7%

Peers

Mkt cap
TickerCompanyMkt cap
COYACoya Therapeutics Inc74.60M
CLNNClene Inc60.34M
IMUXImmunic Inc111.00M
PMNProMIS Neurosciences Inc34.50M
ANVSAnnovis Bio Inc36.02M
ATHEAlterity Therapeutics Ltd ADR44.12M
CGTXCognition Therapeutics Inc64.28M
PLRXPliant Therapeutics Inc48.37M
AMLXAmylyx Pharmaceuticals Inc4.04B
ATRAAtara Biotherapeutics Inc83.32M

Insider trading

1 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
3D Investment Partners Pte. LtFormerly 10% OwnerSep 25 '26Sale2.70640,0001,728,0004,862,047Sep 29 05:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 200
  • MediciNova CEO Provides Shareholder Update (GlobeNewswire)
  • MediciNova to Participate in the Maxim Growth Summit (GlobeNewswire) -5.98%
  • MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints (InvestorsHub) -18.60%
  • MediciNova stock tumbles on mixed Phase 2 NAFLD trial data (Investing.com)
  • MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) (GlobeNewswire)
  • MRNA On Track To Be September's No. 2 S&P 500 Stock But These 5 Smaller Health Care Names Did Even Better (Stocktwits) -5.36%
  • MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast) (GlobeNewswire)
  • MediciNova to Participate in Two Investor Conferences in September (GlobeNewswire) +7.36%
  • MediciNova: Q2 Earnings Snapshot (Associated Press)
  • MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN-166 (ibudilast) in ALS patients (GlobeNewswire)
  • MediciNova CEO Provides Shareholder Update (GlobeNewswire)
  • MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment (GlobeNewswire)
  • MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) (GlobeNewswire)
  • MediciNova: Q1 Earnings Snapshot (Associated Press)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.045-0.063-0.0400.460.083
2026Q12026-05-15-0.050-0.083-0.0530.190.004
2025Q42026-02-20-0.078-0.095-0.0570.150.002
2025Q32025-11-13-0.090-0.120-0.0620.060.001
2025Q22025-08-15-0.122-0.095-0.0670.000.002
2025Q12025-05-13-0.060-0.140-0.0580.00-1
2024Q42025-02-20-0.060-0.055-0.0570.000.002
2024Q32024-11-13-0.060-0.060-0.0580.000.001
2024Q22024-08-08-0.050-0.060-0.0540.000.001
2024Q12024-05-10-0.060-0.050-0.0560.000.001
2023Q42024-02-16-0.080-0.080-0.0420.000.001
2023Q32023-11-09-0.010-0.080-0.0151.000.001
2023Q22023-08-10-0.060-0.070-0.0590.000.001
2023Q12023-05-12-0.060-0.070-0.0600.000.001
2022Q42023-02-17-0.060-0.085-0.0610.000.002
2022Q32022-11-10-0.070-0.090-0.0750.000.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.300-0.349-0.3000.0019.13
2020FY-0.310-0.320-0.3120.000.00
2021FY-0.210-0.253-0.2094.044.01
2022FY-0.290-0.305-0.2870.000.00
2023FY-0.170-0.210-0.1751.001.00
2024FY-0.230-0.220-0.2250.000.00
2025FY-0.240-0.380-0.2400.410.15
2026FY--0.255--0.54
2027FY--0.447--0.50
2028FY-0.080--42.69
2029FY-1.040--126.15
2030FY-1.935--222.57

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-153000.050.000.15
2026Q3S2026-08-142000.080.000.15
2026Q3S2026-07-292000.080.000.15
2026Q3S2026-05-152100.080.000.15
2026Q3S2026-03-152000.060.000.12
2026Q3S2026-03-133000.040.000.12
2026Q3S2026-02-202000.000.000.00
2026Q3S2026-01-022000.000.000.00
2026Q3S2025-11-131000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00

Estimate history

EPS, annual-0.32-0.357-0.3-0.312-0.209-0.287-0.175-0.225-0.245-0.2188
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.054-0.058-0.057-0.058-0.067-0.062-0.057-0.053-0.047
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00004.0380100.410.92
Period201720182019202020212022202320242025TTM
Sales, quarterly00000.1350.1230.1520.1870.458
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual36.45342.08143.90845.02549.04349.04649.04649.04649.22149.221
Period201720182019202020212022202320242025MRQ
Shares, quarterly49.04649.04649.04649.04649.04649.04649.22149.22149.221
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.920.410.001.000.004.040.000.000.00
Cost of Goods Sold Incl. D&A0.630.400.020.020.21-0.020.020.03
Gross Profit0.290.01-0.020.98-0.21--0.02-0.02-0.03
Selling, General and Administrative Excl. Other12.1413.2912.6510.8814.4214.2314.1614.0115.56
Research and Development5.367.137.175.648.938.517.466.065.63
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-11.85-13.28-12.68-9.90-14.63-10.22-14.18-14.03-15.59
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.00--
Net Income Before Taxes-10.75-11.99-11.04-8.57-14.07-10.13-13.86-12.93-14.67
Income Taxes0.010.010.010.000.000.00-0.000.010.01
Consolidated Net Income-10.75-12.00-11.05-8.57-14.07-10.13-13.85-12.94-14.68
Net Income From Continuing Operations-10.75-12.00-11.05-8.57-14.07-10.13-13.85-12.94-14.68
Net Income-10.75-12.00-11.05-8.57-14.07-10.13-13.85-12.94-14.68
EPS (Recurring)-0.22-0.24-0.23-0.17-0.29-0.21-0.31-0.30-0.36
EPS (Basic, Before Extraordinaries)-0.22-0.24-0.23-0.17-0.29-0.21-0.31-0.30-0.36
EPS (Diluted)-0.22-0.24-0.23-0.17-0.29-0.21-0.31-0.30-0.36
EBITDA-11.67-13.09-12.65-9.88-14.42-10.19-14.16-14.01-15.56
Non-Operating Income (Expense)1.101.291.631.330.560.080.321.100.92
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.920.650.940.560.511.252.323.005.00
Price To Sales Ratio70.58156.89-73.57-32.26---
Gross Margin31.142.67-97.97-----
Operating Margin-1,287.41-3,242.47--990.03--253.02---
Net Margin-1,168.20-2,928.78--857.15--251.00---
Shares Outstanding49.2249.2249.0549.0549.0549.0445.0243.9142.08
Market Capitalization68.9168.91103.0073.57100.54131.44236.32295.50342.17

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.460.190.150.120.130.000.000.00
Cost of Goods Sold Incl. D&A0.150.170.150.160.120.010.010.01
Gross Profit0.310.010.00-0.040.01-0.01-0.01-0.01
Selling, General and Administrative Excl. Other2.852.853.093.343.623.203.183.30
Research and Development1.021.261.541.542.181.831.901.85
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.54-2.84-3.09-3.38-3.61-3.20-3.18-3.31
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-2.31-2.59-2.80-3.05-3.28-2.86-2.81-2.85
Income Taxes0.000.000.010.000.000.000.010.00
Consolidated Net Income-2.31-2.59-2.80-3.05-3.28-2.86-2.81-2.85
Net Income From Continuing Operations-2.31-2.59-2.80-3.05-3.28-2.86-2.81-2.85
Net Income-2.31-2.59-2.80-3.05-3.28-2.86-2.81-2.85
EPS (Recurring)-0.05-0.05-0.06-0.06-0.07-0.06-0.06-0.06
EPS (Basic, Before Extraordinaries)-0.05-0.05-0.06-0.06-0.07-0.06-0.06-0.06
EPS (Diluted)-0.05-0.05-0.06-0.06-0.07-0.06-0.06-0.06
EBITDA-2.49-2.79-3.05-3.33-3.60-3.20-3.18-3.30
Non-Operating Income (Expense)0.230.250.300.330.330.340.370.46
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.180.410.180.160.200.290.210.50
Price To Sales Ratio70.58113.02157.08241.51477.35---
Gross Margin68.226.750.13-31.599.80---
Operating Margin-554.31-1,516.60-2,037.97-2,741.67-2,679.88---
Net Margin-504.79-1,383.14-1,846.78-2,473.56-2,437.75---
Shares Outstanding49.2249.2249.2249.0549.0549.0549.0549.05
Market Capitalization68.9167.4364.3862.2964.2571.61103.00103.00

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments30.8140.3651.0058.4971.4360.0463.7962.3127.99
Short Term Receivables0.000.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.180.710.170.500.580.680.510.440.34
Total Current Assets30.9941.0751.1758.9972.0160.7264.3062.7628.33
Net Property, Plant & Equipment0.190.380.620.670.880.060.040.050.06
Total Investments and Advances0.000.000.000.000.000.000.000.000.62
Intangible Assets14.4014.4014.4014.4014.4014.4014.4014.4014.40
Other Assets0.020.020.070.090.120.250.460.010.01
Total Assets45.6055.8866.2774.1587.4175.4279.2177.2243.42
Short Term Debt Incl. Current Port. of LT Debt0.190.190.220.160.130.180.220.000.00
Accounts Payable0.621.101.000.420.400.620.450.620.00
Other Current Liabilities2.981.662.062.612.301.391.561.582.88
Total Current Liabilities3.802.963.283.192.832.192.232.192.88
Long Term Debt0.020.210.410.520.690.000.180.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.200.200.200.200.200.200.200.200.20
Other Liabilities0.000.000.000.000.001.701.701.721.69
Total Liabilities4.023.373.893.913.734.094.314.124.78
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity41.5952.5062.3870.2483.6871.3374.8973.1138.64
Total Shareholders Equity41.5952.5062.3870.2483.6871.3374.8973.1138.64
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity41.5952.5062.3870.2483.6871.3374.8973.1138.64
Total Liabilities & Stockholders Equity45.6055.8866.2774.1587.4175.4279.2177.2243.42
Book Value Per Share0.841.071.271.431.711.581.711.741.06
Tangible Book Value Per Share0.550.780.981.141.411.261.381.400.67
Full-Time Employees6131313119899
Price to Book Ratio1.851.871.141.381.573.323.954.706.65
Return on Assets-23.65-18.09-12.21-17.42-12.45-17.92-16.55-24.33-26.82
Return on Equity-25.50-19.24-12.93-18.28-13.08-18.95-17.49-26.26-30.51
Return on Invested Capital-28.84-20.96-13.65-19.88-12.01-19.42-17.24-20.07-28.89
Quick Ratio8.1613.8815.6118.5125.4227.6728.8628.639.83
Current Ratio8.1613.8815.6118.5125.4227.6728.8628.639.83

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-10.75-12.00-11.05-8.57-14.07-10.13-13.85-12.94-14.68
Depreciation0.280.190.020.020.210.030.020.020.03
Other Funds (Non Cash)0.830.831.371.010.611.933.184.116.31
Funds from Operations-9.65-10.98-9.66-7.54-13.25-8.17-10.66-8.81-8.34
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.541.17-0.980.110.33-1.21-0.17-0.32-0.78
Cash from Operating Activities-9.11-9.81-10.64-7.43-12.91-9.38-10.83-9.12-9.11
Capital Expenditures-0.01-0.00-0.00-0.02-0.01-0.03-0.04-0.01-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.0039.93-40.000.000.000.000.64
Purchase of Investments0.000.000.000.00-59.880.000.000.000.00
Sale Or Maturity of Investments0.000.000.0039.9319.880.000.000.000.64
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.00-0.0039.91-40.01-0.03-0.04-0.010.63
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.240.240.000.000.0120.787.1110.6242.81
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.240.240.000.000.0120.787.1110.6242.81
Proceedsfrom Stock Options0.240.240.000.000.00-0.11-0.190.030.05
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities0.240.240.000.000.0120.787.1110.6242.81
Exchange Rate Effect0.040.020.000.02-0.020.030.00-0.000.00
Net Change in Cash-8.84-9.55-10.6432.49-52.9311.39-3.761.4834.32
Free Cash Flow-9.12-9.81-10.64-7.45-12.92-9.41-10.86-9.14-9.12
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments25.4227.3330.8132.5634.2636.57
Short Term Receivables0.000.250.000.000.130.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.510.570.180.360.731.11
Total Current Assets25.9228.1530.9932.9235.1237.68
Net Property, Plant & Equipment0.110.160.190.240.280.33
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets14.4014.4014.4014.4014.4014.40
Other Assets0.000.000.020.020.020.02
Total Assets40.4342.7045.6047.5849.8252.43
Short Term Debt Incl. Current Port. of LT Debt0.120.170.190.180.180.19
Accounts Payable0.950.850.620.750.570.72
Other Current Liabilities1.892.082.982.411.891.22
Total Current Liabilities2.963.103.803.342.652.13
Long Term Debt0.000.000.020.070.120.17
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.200.200.200.200.200.20
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.163.304.023.612.972.50
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity37.2739.4141.5943.9646.8649.93
Total Shareholders Equity37.2739.4141.5943.9646.8649.93
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity37.2739.4141.5943.9646.8649.93
Total Liabilities & Stockholders Equity40.4342.7045.6047.5849.8252.43
Book Value Per Share0.760.800.840.900.961.02
Tangible Book Value Per Share0.460.510.550.600.660.72
Full-Time Employees--6---
Price to Book Ratio1.851.621.461.331.291.36
Return on Assets-23.83-24.64-23.65-22.73-21.43-19.35
Return on Equity-25.56-26.24-25.50-24.26-22.66-20.33
Return on Invested Capital-6.21-6.56-6.74-6.93-6.99-5.72
Quick Ratio8.759.098.169.8613.2617.66
Current Ratio8.759.098.169.8613.2617.66

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.31-2.59-2.80-3.05-3.28-2.86
Depreciation0.050.040.040.140.010.01
Other Funds (Non Cash)0.180.410.180.060.250.33
Funds from Operations-2.09-2.13-2.58-2.85-3.02-2.53
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.17-1.340.561.140.72-1.26
Cash from Operating Activities-1.92-3.47-2.02-1.70-2.31-3.78
Capital Expenditures0.00-0.010.00-0.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.010.00-0.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.240.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.240.000.000.00
Proceedsfrom Stock Options0.000.000.240.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.000.240.000.000.00
Exchange Rate Effect0.010.000.020.01-0.01-0.00
Net Change in Cash-1.91-3.48-1.76-1.70-2.31-3.79
Free Cash Flow-1.92-3.48-2.02-1.71-2.31-3.78

Revenue breakdown

Pharmaceutical Preparations2025: 409.66K
United States2025: 409.66K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.61%0.3M46.7M323.87K
2026-10-150.63%0.3M46.7M322.08K
2026-09-300.73%0.3M46.7M315.87K
2026-09-150.80%0.4M46.7M57.08K
2026-08-310.79%0.4M46.7M49.15K
2026-08-140.71%0.3M46.7M46.31K
2026-07-310.74%0.3M46.7M44.91K
2026-07-150.66%0.3M46.7M41.58K
2026-06-300.44%0.2M46.7M35.40K
2026-06-150.22%0.1M46.7M38.95K
2026-05-290.37%0.2M46.7M42.31K
2026-05-150.33%0.2M46.7M46.64K
2026-04-300.37%0.2M46.7M52.09K
2026-04-150.36%0.2M46.7M65.30K
2026-03-310.43%0.2M46.7M74.93K
2026-03-130.44%0.2M46.7M74.72K
2026-02-270.42%0.2M46.6M77.00K
2026-02-130.44%0.2M46.6M88.44K
2026-01-300.48%0.2M46.6M927.34K
2026-01-150.58%0.3M46.6M995.55K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.052.95011.000.000.170-0.0090.001
call5.000.000.500.004.93720.000.000.121-0.0120.000
call7.500.000.150.005.9440.000.000.108-0.0130.000
put2.500.001.150.843.7360.000.00-0.830-0.0080.001
put5.002.254.000.009.9960.000.00-0.879-0.0120.000
put7.504.806.500.0011.1690.000.00-0.892-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-30SCHEDULE 13GSEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-288-KCurrent report2026-09-23SEC
2026-09-028-KCurrent report2026-08-31SEC
2026-08-198-KCurrent report2026-08-17SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-248-KCurrent report2026-06-23SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-29ARSAnnual report to security holders. 2025-12-31SEC
2026-04-29DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-23SEC
2026-04-20PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-17PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-23SEC
2026-03-1010-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-208-KCurrent report2026-02-20SEC
2026-01-204Statement of changes in beneficial ownership of securities2026-01-16SEC
2026-01-204Statement of changes in beneficial ownership of securities2026-01-16SEC
2025-12-30424B5SEC
2025-12-308-KCurrent report2025-12-29SEC
2025-12-11EFFECTEffectiveness filing by commission orderSEC
2025-12-09CORRESPSEC
2025-12-05S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2025-11-1210-QQuarterly report pursuant to Section 13 or 15(d)2025-09-30SEC
2025-09-26CORRESPSEC
2025-08-26UPLOADUpload SubmissionSEC
2025-08-22S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2025-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2025-06-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09001.73M1
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Essex Woodlands Management, Inc.2.25%
BlackRock, Inc.1.53%
VANGUARD CAPITAL MANAGEMENT LLC1.24%
CITIGROUP INC1.12%
GEODE CAPITAL MANAGEMENT, LLC1.06%
VANGUARD FIDUCIARY TRUST CO0.57%
RENAISSANCE TECHNOLOGIES LLC0.42%
STATE STREET CORP0.39%
NORTHERN TRUST CORP0.29%
Bank of New York Mellon Corp0.16%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND1.24%
Fidelity Extended Market Index Fund0.51%
iShares Micro-Cap ETF0.32%
Fidelity Total Market Index Fund0.18%
Schwab Total Stock Market Index Fund0.15%
Fidelity Series Total Market Index Fund0.14%
Ultra-Small Company Market Fund0.10%
Fidelity Nasdaq Composite Index Fund0.05%
Small Cap Core Fund0.03%
1290 VT Micro Cap Portfolio0.02%

OakChart. MNOV. Cached 15 minutes.